Thank you, Mike. Total revenue for Q3 ‘15, decreased to 669,846 compared to a strong year-ago performance of $1,283,847 based on the shipment of a few large non-recurring license order in Q3 2014. Q3 2015 license and other revenue decreased to $419,655 compared to $787,720 in Q3 ‘14, and service revenues decreased to $250,191 in Q3 2015 from $496,127 in Q3 2014. The non-recurring custom services decreased due to a custom project that was completed at year-end in 2014. Q3 2015 gross margin was 44% as compared to Q3 2014, principally due to the decrease in higher margin license sales and higher volume hardware sales. Q3 2015 operating expenses rose 5% to $1,382,566 from 1,314,513 in Q3 2014, reflecting both increases in SG&A and R&D expenses related to expanding scope of business, cost related to strategic transitions and R&D efforts focusing the product refresh updates and new product offerings along with the reclassification of roughly 100,000 of Q3 2014 service related R&D expenses to cost of goods sold. BIO-key reported Q3 2015 net loss of $1,079,584 or $0.02 per share compared with a net loss of $51,526 or less than a cent per share in Q3 2014. BIO-key had weighted average number of basic shares outstanding of 66,038,941 and 58,026,262 million in Q3 2015 and Q3 2014 respectively. Per share and per share figures have been adjusted to reflect a February 2015 20-for-1 reverse split. Net cash used for operations during Q3 2015 was 973,836 compared to 1,696,817 in Q4 -- Q3 2014. As of September 30, 2015, BIO-key reported current assets and working capital of $2,426,956 and a loss of $604,256 respectively. Reflecting the impact of the convertible preferred placements and strategic license agreement, as of November 12, 2015, current assets and working capital were approximately $12,800,000 and 11,400,000 respectively. I’ll hand the call back to Mike to review our financial guidance and sales outlook.